{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:04:29Z","timestamp":1777421069228,"version":"3.51.4"},"reference-count":98,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T00:00:00Z","timestamp":1430697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:p>Objective: To review the pharmacology, chemistry, in vitro susceptibility, pharmacokinetics, clinical efficacy, safety, tolerability, dosage, and administration of isavuconazole, a triazole antifungal agent. Data Sources: Studies and reviews were identified through an English language MEDLINE search (1978 to March 2015) and from http:\/\/www.clinicaltrials.gov , Food and Drug Administration (FDA) briefing documents, program abstracts from international symposia, and the manufacturer\u2019s Web site. Study Selection and Data Extraction: All published and unpublished trials, abstracts, in vitro and preclinical studies, and FDA briefing documents were reviewed. Data Synthesis: Isavuconazole has activity against a number of clinically important yeasts and molds, including Candida spp, Aspergillus spp, Cryptococcus neoformans, and Trichosporon spp and variable activity against the Mucorales. Isavuconazole, available for both oral and intravenous administration, is characterized by slow elimination allowing once-daily dosing, extensive tissue distribution, and high (&gt;99%) protein binding. The most commonly reported adverse events, which are mild and limited in nature, include nausea, diarrhea, and elevated liver function tests. Its drug interaction potential appears to be similar to other azole antifungals but less than those observed with voriconazole. Comparative trials are under way or have been recently completed for the treatment of candidemia, invasive candidiasis and aspergillosis, and rare mold infections. Conclusions: Isavuconazole has a broad spectrum of activity and favorable pharmacokinetic properties, providing an advantage over other currently available broad-spectrum azole antifungals and a clinically useful alternative to voriconazole for the treatment of invasive aspergillosis. It may also prove useful for the treatment of candidemia and invasive mold infections; however, these indications await the results of clinical trials.<\/jats:p>","DOI":"10.1177\/1060028015581679","type":"journal-article","created":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T21:52:13Z","timestamp":1430776333000},"page":"825-842","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":76,"title":["Isavuconazole"],"prefix":"10.1177","volume":"49","author":[{"given":"Natasha N.","family":"Pettit","sequence":"first","affiliation":[{"name":"University of Chicago Medicine, University of Chicago Medical Center, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy L.","family":"Carver","sequence":"additional","affiliation":[{"name":"University of Michigan College of Pharmacy, Ann Arbor, MI, USA"},{"name":"University of Michigan Health System, Ann Arbor, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,5,4]]},"reference":[{"key":"bibr1-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1086\/322606"},{"key":"bibr2-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-013-1944-3"},{"key":"bibr3-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit136"},{"key":"bibr4-1060028015581679","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0247"},{"key":"bibr5-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e32835c1fc2"},{"key":"bibr6-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.279-285.2006"},{"key":"bibr7-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(02)00892-2"},{"key":"bibr8-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.12.4.501"},{"key":"bibr9-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1108-6"},{"key":"bibr10-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1233"},{"key":"bibr11-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01530-08"},{"key":"bibr12-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki399"},{"key":"bibr13-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04055-14"},{"key":"bibr14-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/aac.04055-14"},{"key":"bibr15-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00636-13"},{"key":"bibr16-1060028015581679","volume-title":"Isavuconazole and Nine Comparator Antifungal Susceptibility Profiles for Common and Uncommon Opportunistic Fungi Collected in 2013: Application of New Clinical Breakpoints and Epidemiological Cutoff Values","author":"Pfaller MA","year":"2014"},{"key":"bibr17-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.03.004"},{"key":"bibr18-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01512-07"},{"key":"bibr19-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01217-06"},{"key":"bibr20-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.06.003"},{"key":"bibr21-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00863-13"},{"key":"bibr22-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-013-0570-4"},{"key":"bibr23-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1093\/mmycol\/myu016"},{"key":"bibr24-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.02.023"},{"key":"bibr25-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.10.2645"},{"key":"bibr26-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn076"},{"key":"bibr27-1060028015581679","volume-title":"Outcomes by Minimum Inhibitory Concentrations from Isavuconazole Phase 3 Trial of Invasive Aspergillosis (SECURE)","author":"Andes D","year":"2014"},{"key":"bibr28-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2010.01996.x"},{"key":"bibr29-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/aac.03779-14"},{"key":"bibr30-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01190-13"},{"key":"bibr31-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.08.006"},{"key":"bibr32-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01384-07"},{"key":"bibr33-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12039"},{"key":"bibr34-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01190-13"},{"key":"bibr35-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01115-12"},{"key":"bibr36-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06252-11"},{"key":"bibr37-1060028015581679","doi-asserted-by":"publisher","DOI":"10.3109\/13693781003690067"},{"key":"bibr38-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00746-10"},{"key":"bibr39-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.06750-11"},{"key":"bibr40-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-289"},{"key":"bibr41-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00646-08"},{"key":"bibr42-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01216-08"},{"key":"bibr43-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00685-10"},{"key":"bibr44-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02222-08"},{"key":"bibr45-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp138"},{"key":"bibr46-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2009.21.3.272"},{"key":"bibr47-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1080\/13693780802562969"},{"key":"bibr48-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12234"},{"key":"bibr49-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01420-10"},{"key":"bibr50-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-013-0552-6"},{"key":"bibr51-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05910-11"},{"key":"bibr52-1060028015581679","volume-title":"Treated With Isavuconazole: Experience From the VITAL and SECURE Trials","author":"Cornely OA","year":"2014"},{"key":"bibr53-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku505"},{"key":"bibr54-1060028015581679","volume-title":"Outcomes in Patients with Invasive Fungal Disease Caused by Dimorphic Fungi Treated with Isavuuconazole: Experience From the VITAL Trial. American Society for Microbiology Infectious Diseases Society of America (IDSA) 54th Annual Meeting American Society for Microbiology and Infectious Diseases Society of America","author":"Thompson G","year":"2014"},{"key":"bibr55-1060028015581679","volume-title":"In Vitro Activity of a New Triazole, BAL8557, Against Histoplasma capsulatum From Patients Failing Fluconazole","author":"Wheat L","year":"2006"},{"key":"bibr56-1060028015581679","doi-asserted-by":"publisher","DOI":"10.3109\/13693786.2011.583285"},{"key":"bibr57-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1586\/eri.09.18"},{"key":"bibr58-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4914(02)02280-3"},{"key":"bibr59-1060028015581679","volume-title":"Comparison Between Isavuconazole and Other Azoles Against Characterised Clinical Isolates and Yeast Model Systems","author":"Sanglard D","year":"2008"},{"key":"bibr60-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.3.1120-1124.2003"},{"key":"bibr61-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2006.01.001"},{"key":"bibr62-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.7.2747-2750.2004"},{"key":"bibr63-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01092-06"},{"key":"bibr64-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr443"},{"key":"bibr65-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01189-10"},{"key":"bibr66-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01355-13"},{"key":"bibr67-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01354-13"},{"key":"bibr68-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01331-12"},{"key":"bibr69-1060028015581679","volume-title":"Pharmacodynamics of BAL4815, a New Azole Antifungal in a Mouse Model of Systemic Infection","author":"te Dorsthorst DTA","year":"2004"},{"key":"bibr70-1060028015581679","volume-title":"Paper presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases, ECCMID","author":"Warn PA","year":"2008"},{"key":"bibr71-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01601-08"},{"key":"bibr72-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.286-293.2006"},{"key":"bibr73-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00319-09"},{"key":"bibr74-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku311"},{"key":"bibr75-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/aac.04569-14"},{"key":"bibr76-1060028015581679","unstructured":"Advisory Committee Briefing Document. Isavuconazonium: invasive aspergillosis and invasive mucormycosis. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM430748.pdf. Accessed March 29, 2015."},{"key":"bibr77-1060028015581679","volume-title":"Isavuconazole (ISA) Population Pharmacokinetic Modeling From Phase 1 and Phase 3 Clinical Trials and Target Attainment Analysis","author":"Desai A","year":"2014"},{"key":"bibr78-1060028015581679","unstructured":"Schmitt-Hoffmann A, Roos B, Roerhle M, No relevant food effect in man on isavuconazole oral pharmacokinetics preliminary data. Paper presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology; October 25-28, 2008; Washington, DC. Abstract A-008."},{"key":"bibr79-1060028015581679","volume-title":"No Relevant Food Effect in Man on Isavuconazole Oral Pharmacokinetics: Preliminary Data. ICAAC American Society for Microbiology -Infectious Diseases Society of America (IDSA) 46th Annual Meeting American Society for Microbiology and Infectious Diseases Society of America","author":"Schmitt-Hoffmann A","year":"2008"},{"key":"bibr80-1060028015581679","volume-title":"A Phase 3 Randomized, Double-Blind, Non-Inferiority Trial Evaluating Isavuconazole (ISA) vs Voriconazole (VRC) for the Primary Treatment of Invasive Mold Infection (SECURE): Outcomes in Subset of Patients with Hematologic Malignancies (HM)","author":"Marr KA","year":"2014"},{"key":"bibr81-1060028015581679","volume-title":"A Phase 3 Randomized, Double-Blind, Non-Inferiority Trial Evaluating Isavuconazole (ISA) vs Voriconazole (VRC) for the Primary Treatment of Invasive Fungal Disease (IFD) Caused by Aspergillus spp. or other Filamentous Fungi (SECURE): Outcomes by Malignancy Status","author":"Ullmann AJ","year":"2014"},{"key":"bibr82-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn409"},{"key":"bibr83-1060028015581679","unstructured":"FDA briefing document: Anti-infective Drugs Advisory Committee Meeting January 22, 2015. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM430747.pdf. Accessed March 29, 2015."},{"key":"bibr84-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.12.1730"},{"key":"bibr85-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.6.719"},{"key":"bibr86-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn431"},{"key":"bibr87-1060028015581679","volume-title":"Dose Response Curves and Dose Fractionation Studies with BAL8557 in a Murine Model of Disseminated Aspergillosis","author":"Warn PA","year":"2006"},{"key":"bibr88-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02301-13"},{"key":"bibr89-1060028015581679","volume-title":"Isavuconazole Treatment of Disseminated Zycomycosis","author":"Gagne LS","year":"2011"},{"key":"bibr90-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12098"},{"key":"bibr91-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.03176-13"},{"key":"bibr92-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1128\/aac.04586-14"},{"key":"bibr93-1060028015581679","unstructured":"Astellas Pharma Inc. Isavuconazole (BAL8557) in the treatment of candidemia and other invasive candida infections. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00413218?term=NCT00444366&rank=1. Accessed March 29, 2015."},{"key":"bibr94-1060028015581679","unstructured":"Basilea Pharmaceutica. Press release. http:\/\/www.basilea.com\/News-and-Media\/Basilea-and-Astellas-update-isavuconazole-phase-III-trial-in-consultation-with-FDA\/385. Accessed March 29, 2015."},{"key":"bibr95-1060028015581679","volume-title":"Successful Outcomes in Patients With Invasive Fungal Disease Due to C. gattii and C. neoformans Treated With Isavuconazole: Experience From the VITAL Trial","author":"Queiroz-Torres F","year":"2014"},{"key":"bibr96-1060028015581679","unstructured":"Astellas Pharma Inc. Isavuconazole in the treatment of renally impaired aspergillosis and rare fungi. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00634049?term=NCT00634049&rank=1. Accessed March 29, 2015."},{"key":"bibr97-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.761135"},{"key":"bibr98-1060028015581679","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032868"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028015581679","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028015581679","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028015581679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:47Z","timestamp":1777374947000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028015581679"}},"subtitle":["A New Option for the Management of Invasive Fungal Infections"],"short-title":[],"issued":{"date-parts":[[2015,5,4]]},"references-count":98,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1177\/1060028015581679"],"URL":"https:\/\/doi.org\/10.1177\/1060028015581679","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,4]]}}}